The UK and US have forged a key bilateral deal that will preserve no duties on UK pharmaceutical shipments entering the American market.
The Terms of the Accord
As part of the deal, the UK has committed to raise funding on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that tariffs on these vital goods will be held at nothing for a period of 36 months.
This agreement comes after previous threats to hike tariffs on patented pharmaceutical products, with increases floated up to 100%.
"This agreement with the United Kingdom reinforces the worldwide climate for innovative medicines and brings long-overdue fairness to U.S.–U.K. medicine commerce," an announcement said.
Commercial Impact
Drugs are one of the Britain's biggest goods shipped to the United States, which is easily the biggest buyer for major British pharmaceutical firms.
Export figures show that in the one-year period to the end of the third quarter, the UK exported pharmaceutical products totaling billions to the US. This value represented a significant portion of total UK exports in that timeframe.
"This guarantee safeguards jobs, increases investment and paves the way for the UK to emerge as a worldwide center for medical research," a minister remarked.
Specific UK Commitments
The deal includes several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the affordability limit at which it considers new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a target to raise total public funding on treatments from 0.3% of GDP to 0.6 percent over the next decade.
- Rebate Cap: The amount drug companies must return to the NHS to control costs will be restricted at 15%. In the past, repayments exceeded twenty percent.
Broader Context
This agreement follows a ongoing row between the drug companies and the ministers over drug pricing and approval rates.
This friction were exacerbated by assertions that US patients were paying a premium for the identical medicines than patients in the other developed nations.
Recently, several significant manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been pledged toward American operations.
One official stated that the NHS must spend more on drugs, noting that its expenditure on drugs had declined as a percentage of its resources over the past decade.
